CraniUS Closes ~$20 Million Series A Funding Round
The investment will enable CraniUS to scale its product development to facilitate chronic and direct medicine delivery to help effectively treat brain diseases
BALTIMORE, Md., Sept. 27, 2022 /PRNewswire/ -- CraniUS LLC, an R&D company focused on building groundbreaking treatments for patients with chronic brain disease, today announced the closing of a $19.4 million Series A fundraising round.
The Series A round, funded entirely by private investors, will drive the development of CraniUS' flagship device as it moves towards FDA approval for a first-in-human clinical study. The forthcoming phase will build off successful pre-clinical studies in which the device will validate safety and efficacy in delivering medicine directly to the brain, bypassing the blood-brain barrier.